NextCure (NXTC) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, to be held virtually, allowing electronic voting and questions.

• Key business includes director elections, auditor ratification, advisory say-on-pay, and an amendment to the 2019 Omnibus Incentive Plan.

• Focus remains on developing innovative cancer therapies, especially for patients unresponsive to current treatments.

• Forward-looking statements highlight ongoing clinical trials and anticipated milestones in 2026.

Voting matters and shareholder proposals

• Election of two Class I directors (Anne Borgman, M.D. and John G. Houston, Ph.D.) for three-year terms.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Approval of an amendment and restatement of the 2019 Omnibus Incentive Plan to increase authorized shares.

Board of directors and corporate governance

• Board consists of seven members, majority independent, with diverse expertise in biotech, finance, and governance.

• Chair and CEO roles are separated to reinforce board independence.

• Committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Regular executive sessions and annual CEO succession planning.

• Code of business conduct and ethics, insider trading, and clawback policies in place.